Related Experiment Video
Updated: May 12, 2025
09:16
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
Published on: June 21, 2019
25.4K
Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study
Hwa Yeon Ko1, Dongwon Yoon1,2, Ju Hwan Kim1,2
1School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Epidemiology and Health
|May 9, 2025
Summary
COVID-19 vaccination does not increase the risk of new-onset seizures (NOS). This study provides safety evidence for clinical decisions and public confidence in COVID-19 vaccines.
Area of Science:
- Neurology
- Vaccinology
- Public Health
Background:
- Reports of new-onset seizures (NOS) post-COVID-19 vaccination exist, but safety data are limited.
- Investigating the association between COVID-19 vaccination and NOS is crucial for vaccine safety assessment.
Purpose of the Study:
- To evaluate the risk of new-onset seizures (NOS) following COVID-19 vaccination.
- To provide robust safety evidence for COVID-19 vaccines.
Main Methods:
- A self-controlled case series study using nationwide databases (February 2021-October 2022).
- Included adults (≥18 years) vaccinated with BNT162b2, ChAdOx1 nCoV-19, mRNA-1273, NVX-CoV2373, or Ad26.COV2.S.
- Compared NOS risk in a 28-day window post-vaccination versus the remaining observation period.
Main Results:
- No increased risk of NOS was found within 28 days post-vaccination (IRR, 0.99; 95% CI, 0.94-1.05).
- Subgroup analyses showed no significant increase for most vaccines.
- A marginally elevated risk was observed for mRNA-1273 (IRR, 1.21; 95% CI, 1.04-1.42).
Conclusions:
- COVID-19 vaccination is not associated with an increased risk of new-onset seizures.
- Findings support the safety of COVID-19 vaccines and aid clinical decision-making.
- This evidence can enhance public trust in COVID-19 vaccination programs.
More Related Videos
Related Concept Videos
01:13Seizures: Classification
284
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
284
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
260
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
260
01:14Antiepileptic Drugs: Glutamate Antagonists
249
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
249
01:08Antiepileptic Drugs: Sodium Channel Blockers
262
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
262
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
187
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
187
01:20Antiepileptic Drugs: Potassium Channel Activators
126
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
126